Cerebrolysin: Evidence, Mechanism, Dosing & Legal Status

Cerebrolysin (developmental code FPF-1070) is a low-molecular-weight peptide-and-amino-acid mixture produced by standardized enzymatic hydrolysis of purified porcine brain protein, marketed since the mid-20th century by EVER Neuro Pharma of Austria as a "neurotrophic" agent for stroke, traumatic brain injury and dementia.121 Unlike most peptides in the research-chemical space, it has a genuinely large human-trial record — but that record is deeply contested. This monograph separates what the randomized data show from how that signal is disputed.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Cerebrolysin is not an FDA-approved drug and has no legal U.S. human-use pathway. Dosing figures are reported strictly as seen in the published literature and approved foreign labeling for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Cerebrolysin and how does it work?

Cerebrolysin is not a single molecule but a defined mixture produced by controlled enzymatic cleavage of purified, lipid- and antigen-depleted porcine brain protein.113 It is reported to be roughly 25% low-molecular-weight peptides (under 10,000 Da) and 75% free amino acids, the small peptide fraction being the portion thought capable of crossing the blood-brain barrier; each mL is standardized to about 215.2 mg of peptide concentrate.113

Mechanistically — and almost entirely at the preclinical level — Cerebrolysin is described as a neurotrophic modulator whose constituents are claimed to mimic the activity of endogenous neurotrophic factors: brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell-line-derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF).12 Proposed pathways include Trk-receptor signaling supporting neuronal survival, synaptic plasticity and neurogenesis; reduction of glutamate excitotoxicity; antioxidant and anti-apoptotic effects; and modulation of amyloid-precursor-protein processing.121 The Cochrane authors note candidly that "its specific molecular effects are not clear," and because the product is a heterogeneous mixture rather than a single agent, classical single-compound pharmacokinetics do not apply — there is no standard half-life or bioavailability profile, and constituent peptides are short-lived in circulation.12 From a functional standpoint the multi-target, repair-supporting framing is conceptually attractive, but a plausible mechanism is not efficacy, and for Cerebrolysin the human outcome data, not the mechanism, are where the controversy lives.

What is the evidence by indication?

The defining feature of Cerebrolysin is that human RCTs unquestionably exist for every major indication. The central problem is not the absence of human data but its conflict — manufacturer-associated trials and meta-analyses are positive, while the manufacturer-independent Cochrane synthesis for acute stroke is null-to-negative and flags a possible harm signal. The grades below reflect that a randomized evidence base exists (justifying A), with the qualifier in each row being the contested, sponsor-correlated direction of effect.

The most authoritative independent synthesis is the 2023 Cochrane review of acute ischemic stroke (7 RCTs, 1,773 participants), which found Cerebrolysin probably results in little to no difference in all-cause death (RR 0.96, 95% CI 0.65-1.41) and — importantly — moderate-certainty evidence of a possible increase in non-fatal serious adverse events (RR 2.39, 95% CI 1.10-5.23), worse in the 30 mL × 10-day subgroup.1 The review notes the manufacturer supported three multicenter trials and that two (CASTA and CERE-LYSE-1) were judged high risk of other bias due to direct manufacturer involvement, with European stroke guidelines advising against use; the large CASTA trial (about 1,070 patients) did not show a significant benefit.1 By contrast, a manufacturer-independent safety meta-analysis of 12 RCTs (2,202 patients) found safety comparable to placebo, including serious adverse events at RR 0.99 (95% CI 0.74-1.32) — a discrepancy traced to different trial sets and outcome definitions.3

The positive signals come from sponsor-associated work. The CARS trial randomized 208 patients to 30 mL/day IV for 21 days plus rehabilitation and reported large motor superiority on the Action Research Arm Test at day 90 (mean change +30.7 vs +15.9 points, P less than 0.0001) — but the authors themselves framed it as an exploratory study needing a confirmatory Phase III.210 For TBI, the CAPTAIN series prospective meta-analysis (185 patients) found a small-to-medium effect favoring Cerebrolysin on a multidimensional endpoint at day 90 (MW 0.60, SMD 0.34), though the composite was designed by the sponsor's statistical team and the total sample is small.45 The most internally consistent positive data are in cognition: a 2013 Cochrane review (6 RCTs, 597 participants) found beneficial effects on MMSE and ADAS-cog in vascular dementia, a 2024 network meta-analysis (13 RCTs, 3,880 patients) ranked it favorably, and a 2015 Alzheimer's meta-analysis found a cognitive benefit at 4 weeks that was no longer significant at 6 months.786 Even these come largely from overlapping research networks.

What doses appear in the literature?

Reported strictly as information, not a protocol or recommendation — Cerebrolysin has no FDA-approved label and no legal U.S. human-use pathway. The route is parenteral only: slow IV infusion (diluted, typically over 20 to 60 minutes) is the main research route, with IM injection used for smaller volumes; there is no oral form, and the product is supplied ready-made requiring no reconstitution.1312 Acute-stroke trials commonly used 30 mL/day (some up to 50 mL/day) for about 10 to 21 days.13 The CARS post-stroke rehabilitation trial used 30 mL/day IV for 21 days started 24 to 72 hours post-stroke.2 The CAPTAIN TBI series used 50 mL/day for 10 days then two cycles of 10 mL/day, and dementia and Alzheimer's trials used 30 mL/day.56 Foreign labeling lists general ranges from about 5 mL/day for lighter cognitive courses up to 10-50 mL/day over 10-28-day courses, with compatibility cautions against lipid-containing and pH-altering solutions.13

How safe is Cerebrolysin?

Across trials and foreign labeling, reactions are generally transient and mild: dizziness, fatigue, headache, nausea, sweating, injection-site reactions and transient temperature change, with rapid IV infusion occasionally causing heat sensations or, rarely, hypotension.1312 The independent 12-RCT safety pool found no significant difference versus placebo in serious adverse events, any AE or mortality.3 The principal caveat is the opposite signal from the 2023 Cochrane review: moderate-certainty evidence of a possible increase in non-fatal serious adverse events (RR 2.39, 95% CI 1.10-5.23), more pronounced at 30 mL × 10 days — the single most important safety consideration and the reason European stroke guidance advises against use.1 Because the product is porcine-derived biological material, hypersensitivity and rare anaphylaxis are possible, and seizure is a recognized rare serious event underlying the epilepsy contraindication.13 Contraindications include hypersensitivity to constituents or porcine products, epilepsy or status epilepticus, severe renal impairment, and pregnancy and breastfeeding (no adequate human safety data).1312

What is the FDA and WADA status in 2026?

Cerebrolysin is not approved by the U.S. FDA for any indication, and no U.S. New Drug Application has ever been reviewed.12 As a proprietary, undefined porcine-derived biological mixture rather than a single bulk drug substance, it has no 503A or 503B compounding pathway, so no U.S.-licensed physician can lawfully prescribe or compound it; in the United States it may be handled only as a non-human research reagent, and gray-market imports sold as "Cerebrolysin" are unregulated with no guarantee of identity, sterility or dose.12 Internationally it is approved and marketed in 45-plus countries — Russia, much of Eastern Europe, China and other Asian and post-Soviet states — under varying, often older evidentiary standards not equivalent to FDA review, while European clinical-stroke guidance advises against its use.121

For athletes the status is cautionary rather than explicit. Cerebrolysin is not named on the 2026 WADA Prohibited List, but that list is non-exhaustive, and a substance not approved for human therapeutic use by any governmental regulatory authority falls under the S0 non-approved-substances catch-all.14 A competitive athlete should therefore treat Cerebrolysin as high anti-doping risk, remember that strict liability applies, and verify status via GlobalDRO or their national anti-doping organization before any use.14

Bottom line. Cerebrolysin pairs a large, genuine human-RCT evidence base with an unusually unsettled verdict — studied extensively, proven inconclusively. Manufacturer-associated trials consistently report modest-to-large benefit while the independent 2023 Cochrane stroke synthesis found no benefit on death or dependence and a probable rise in non-fatal serious adverse events; the most internally consistent positive signal is in vascular-dementia and Alzheimer's cognition, though largely from overlapping networks and faded by 6 months in AD. For a U.S. reader the practical reality is dispositive: not FDA-approved, no compounding pathway, no legal human-use route, and treated as a non-human research reagent — with healthy-enhancement claims unproven (Grade D). Regulatory facts here are current as of June 2026 and should be re-verified for any later change.